<DOC>
	<DOC>NCT01512849</DOC>
	<brief_summary>The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.</brief_summary>
	<brief_title>A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment</brief_title>
	<detailed_description>This is an open-label, randomized, 2-way crossover study to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment relative to patients with type 2 diabetes mellitus who have normal renal function. The patients will receive both TA-7284-Low and TA-7284-High orally alone in either Period 1 or 2.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus in stable condition who have normal renal function or moderate renal impairment Body mass index of ≥18.5 kg/m2 and ≤39.9 kg/m2 at screening HbA1c of ≥6.5% and ≤10.5% at screening Type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus Past or current history of severe diabetic complications Patients requiring insulin therapy History of hereditary glucosegalactose malabsorption or primary renal glucosuria</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Sodium Glucose Co-transporter2 (SGLT2) inhibitor</keyword>
</DOC>